SLC5A2 and diabetes mellitus: The treatment with SGLT2, for a median duration of 5 years, with an interquartile range of 4 to 6 years, resulted in significant improvements in risk biomarkers associated with diabetes complications and CV events (weight, BMI, WC, SBP, DBP, FPG, HbA1c (Figure 1), LDLc, triglycerides, and UACR).